Chief Executive Officer & Chairman of the Board of Directors
Kathy Ordoñez is the Chief Executive Officer and Chairman of the Board of Directors at RainDance Technologies. Ms. Ordoñez became a member of the Board of Directors in July 2014, Chairman of the Board in September 2015 and Chief Executive Officer in June 2016. She brings more than 30 years of experience in the life sciences and diagnostics industries. Previously, Ms. Ordoñez was a Senior Vice President at Quest Diagnostics where she was initially responsible for leading the company’s R&D effort and later provided oversight to multiple businesses commercializing diagnostic products and testing services. She joined Quest Diagnostics as part of its acquisition of Celera Corporation in 2011. Ms. Ordoñez was previously the Chief Executive Officer at Celera and a founder of Celera Diagnostics. Under her leadership, Celera became the leading provider of genetic testing products for HIV resistance, cystic fibrosis and high complexity tissue transplantation. Earlier in her career, Ms. Ordoñez held several senior positions at Hoffmann-La Roche, overseeing the formation of Roche Molecular Systems, where she served as President and Chief Executive Officer, and led the wide-scale commercial application of the Polymerase Chain Reaction (PCR) technology to the research, diagnostic and forensic fields.
Alfred G. Merriweather
Chief Financial Officer
Mr. Merriweather brings more than 25 years of executive level experience in private and public company financing, mergers and acquisitions, as well as broad transactional experience in strategic corporate partnerships and initial public offerings. He most recently served as CFO of Verinata Health Inc. prior to its acquisition by Illumina. Previously he served as CFO and in senior executive positions with several leading clinical diagnostics and life science companies, including Celera Corporation and Monogram Biosciences, which were later acquired by Quest Diagnostics and LabCorp, respectively. Mr. Merriweather holds B.A. and M.A. degrees in Economics from Cambridge University in the U.K. He has served as a member of the Board of Directors for the Association of Bioscience Finance Officers and is a former member of the Institute of Chartered Accountants in England and Wales.
Darren R. Link, Ph.D.
Co-Founder and Chief Technology Officer
Dr. Link holds a B.S. degree in physics from Montana State University and a Ph.D. in physics from the University of Colorado. Before joining RainDance, he spent 2 years at Harvard University as a postdoctoral scientist studying soft materials physics in the department of physics and division of engineering and applied sciences. Dr. Link spent 2 years at Tokyo Institute of Technology as a postdoctoral scientist studying liquid crystalline materials. He has received grant funding from the U.S. Defense Advanced Research Projects Agency and participated in the National Science Foundation’s U.S.-Japan exchange program for young scientists in Nanotechnology. Dr. Link has co-authored more than 60 peer-reviewed articles and 20 patent applications. He also serves on the Industrial Advisory Board of the Vanderbilt Institute for Integrative Biosystems Research and Education.
Chief Operating Officer
Mr. Kelly joined RainDance from Synarc, Inc., where he served as Vice President, Clinical Operations. He has over 30 years of management experience, with more than 25 years in life sciences. Mr. Kelly was Chief Operating Officer at Protedyne, a leader in bringing the industrial design for automation philosophy to genome-based drug research. He also was Vice President of Clinical Operations, North America and Worldwide Business Operations for PAREXEL International and was Executive Director of Manufacturing Operations at Chiron Diagnostics. Mr. Kelly holds a B.S. in finance from Miami (Ohio) University, and a MBA from Syracuse University.
Scott R. Bortner, Ph.D., J.D.
Vice President of Intellectual Property
Dr. Bortner brings more than 25 years of experience leading teams to create, grow and protect some of the genomics industry’s largest IP portfolios, including patents, trade secrets, copyrights, and trademarks. During his career, he has held senior IP Counsel positions at leading law firms and life sciences companies including Applied Biosystems, Affymetrix and Natera. As a senior attorney for Applied Biosystems, Dr. Bortner managed legal teams; filed patents; counseled management and scientists; performed extensive freedom to operate analyses and due diligence; drafted licenses; and managed litigation. He also provided the patent due diligence for the $725 million acquisition of Ion Torrent in 2010. Dr. Bortner holds a Ph.D. in Microbiology and Molecular Genetics from Harvard University, a B.A. in Biochemistry from Cornell University, and a J.D. degree from Santa Clara University School of Law.
VP Commercial, North America
Ms. Emrick brings 20 years of experience and commercial leadership in the life science industry. She has held Senior Director of Marketing positions at RainDance Technologies and Courtagen Life Sciences, a CLIA laboratory specializing in genetic testing for neurological disorders. Throughout her career she led successful commercial efforts and sales teams at Applied Biosystems, a global leader in biotechnology reagents and systems. Following the $6.7 billion merger of Invitrogen and Applied Biosystems, Ms. Emrick served in Vice President, Commercial roles at Life Technologies. She holds a B.S. degree in Biotechnology, Molecular Biology from Worcester Polytechnic Institute.
Yafei Lui, Ph.D.
Vice President, Commercial Operations, Europe and Asia
Dr. Liu received his BS, PhD education at Peking University, and University of Southern California. He then received postdoctoral training in cancer molecular biology, at Stanford University and UC Berkeley. He has published 11 peer reviewed articles while receiving his academic trainings. Dr. Liu has 20 years life sciences industry experience, while working at Applied Biosystems, Illumina, Life Technologies, then RainDance Technologies. During this time, he has transitioned from R&D into increasing sales and commercial management roles. Dr. Liu has been able to establish a successful sales and commercial management track record in the past decade, due to his abilities to understand and address customers’ needs accurately and efficiently, so that he can help his customers to be successful while achieving company’s commercial goals.
John A. Luckey, Ph.D.
Vice President of Product Development
Dr. Luckey brings more than 20 years of experience leading teams tasked with developing biotechnology systems and technology platforms. During his career, he has held senior product and platform development positions in companies including Roche NimbleGen, where he directed research and development activities for improving and expanding the company’s core DNA microarray synthesis technology and related instrumentation. At Roche, he also liaised with 454 Life Sciences development teams and participated on the global team tasked with defining a strategy for applying NGS technology to high-value clinical diagnostics applications. Dr. Luckey also managed product development and engineering activities at MJ Research, contributing to the design and development of the Opticon product family and Opticon Monitor software. In 1994, he founded GeneSys Technologies and brought to market the BaseStation DNA Fragment Analyzer, an ultrathin gel electrophoresis system he designed, developed and patented. Dr. Luckey holds a Ph.D. in Analytical Chemistry and an M.B.A. in Executive Management from the University of Wisconsin, Madison.